WO1998005308A3 - Terazosin capsules - Google Patents
Terazosin capsules Download PDFInfo
- Publication number
- WO1998005308A3 WO1998005308A3 PCT/EP1997/004175 EP9704175W WO9805308A3 WO 1998005308 A3 WO1998005308 A3 WO 1998005308A3 EP 9704175 W EP9704175 W EP 9704175W WO 9805308 A3 WO9805308 A3 WO 9805308A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- terazosin
- capsules
- dosage form
- capsule dosage
- filled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU40130/97A AU4013097A (en) | 1996-08-01 | 1997-07-31 | Terazosin capsules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/691,907 | 1996-08-01 | ||
US08/691,907 US5952003A (en) | 1996-08-01 | 1996-08-01 | Terazosin capsules |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998005308A2 WO1998005308A2 (en) | 1998-02-12 |
WO1998005308A3 true WO1998005308A3 (en) | 1998-04-23 |
Family
ID=24778454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/004175 WO1998005308A2 (en) | 1996-08-01 | 1997-07-31 | Terazosin capsules |
Country Status (3)
Country | Link |
---|---|
US (2) | US5952003A (en) |
AU (1) | AU4013097A (en) |
WO (1) | WO1998005308A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
US7235543B2 (en) * | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
EP1606287B1 (en) * | 2003-03-07 | 2013-10-02 | Merck Sharp & Dohme Corp. | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
JP2009542677A (en) * | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | Solid formulation of thrombin receptor antagonist |
ES2813400T3 (en) * | 2009-05-12 | 2021-03-23 | Galenica Ab | Monetasone and propylene glycol oil-in-water emulsion |
ES2385240B1 (en) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES. |
CN112007009A (en) * | 2020-07-28 | 2020-12-01 | 重庆华森制药股份有限公司 | Intelligent manufacturing method and system of terazosin hydrochloride capsule |
US11224572B1 (en) | 2020-08-17 | 2022-01-18 | Novitium Pharma LLC | Stable oral liquid composition of terazosin |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212176A (en) * | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
WO1993019758A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compositions and methods for treating benign prostatic hypertrophy |
US5294615A (en) * | 1993-04-29 | 1994-03-15 | Abbott Laboratories | Terazosin polymorph and pharmaceutical composition |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
US4092315A (en) * | 1976-03-01 | 1978-05-30 | Pfizer Inc. | Novel crystalline forms of prazosin hydrochloride |
GB1591490A (en) * | 1977-08-04 | 1981-06-24 | Abbott Lab | 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate |
US5122514A (en) * | 1990-04-23 | 1992-06-16 | Abbott Laboratories | Psoriasis treatment |
US5412095A (en) * | 1993-04-29 | 1995-05-02 | Abbott Laboratories | Terazosin monohydrochloride and processes and intermediate for its production |
US5504207A (en) * | 1994-10-18 | 1996-04-02 | Abbott Laboratories | Process and intermediate for the preparation of terazosin hydrochloride dihydrate |
US5587377A (en) * | 1995-10-24 | 1996-12-24 | Invamed, Inc. | Terazosin crystalline polymorph and pharmaceutical compositions thereof |
DE19546573A1 (en) * | 1995-12-13 | 1997-06-19 | Uetikon Chemie Gmbh | Crystalline polymorph of terazosin hydrochloride, and process for its preparation |
US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
-
1996
- 1996-08-01 US US08/691,907 patent/US5952003A/en not_active Expired - Lifetime
-
1997
- 1997-07-31 AU AU40130/97A patent/AU4013097A/en not_active Abandoned
- 1997-07-31 WO PCT/EP1997/004175 patent/WO1998005308A2/en active Application Filing
-
1999
- 1999-05-18 US US09/313,613 patent/US6110493A/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212176A (en) * | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
WO1993019758A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compositions and methods for treating benign prostatic hypertrophy |
US5294615A (en) * | 1993-04-29 | 1994-03-15 | Abbott Laboratories | Terazosin polymorph and pharmaceutical composition |
US5362730A (en) * | 1993-04-29 | 1994-11-08 | Abbott Laboratories | Terazosin polymorph and pharmaceutical composition |
Non-Patent Citations (2)
Title |
---|
SUCKER H. ET AL: "Pharmazeutische Technologie", 1991, THIEME VERLAG, STUTTGART, XP002056329, 189560 * |
UNITED STATES PHARMACOPEIAL CONVENTION, INC: "The United States Pharmacopeia. The National Formulary", 1995, UNITED STATES PHARMACOPEIAL CONVENTION, INC, ROCKVILLE, XP002056328 * |
Also Published As
Publication number | Publication date |
---|---|
US6110493A (en) | 2000-08-29 |
WO1998005308A2 (en) | 1998-02-12 |
US5952003A (en) | 1999-09-14 |
AU4013097A (en) | 1998-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2219988A (en) | Drug capsule | |
WO1998005308A3 (en) | Terazosin capsules | |
EP0180287A3 (en) | A cellulose ether composition and a hard medicinal capsule prepared therefrom | |
GB2238478B (en) | Gel filled capsule formulations of a benzodiazepine | |
AU589866B2 (en) | Sustained release capsule | |
GB8618153D0 (en) | Granular delayed-release form of pharmaceutically active substances | |
IL84757A0 (en) | Spiro-substituted glutaramide derivatives and pharmaceutical compositions containing them | |
IL84855A (en) | Hydrosols of pharmacologically active agents,their preparation and pharmaceutical compositions containing them | |
EP0098041A3 (en) | Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use | |
AU3924285A (en) | Oral medicine capsule | |
IL85312A0 (en) | Improving the stability of pharmaceutical compositions | |
DK499181A (en) | QUICK-DISINTEGRATING COMPRESSED PHARMACEUTICAL PREPARATIONS | |
GB8705608D0 (en) | Preparation of tablets | |
HUP9900751A3 (en) | Stable pharmaceutical forms of administration containing parathormone | |
GB8506656D0 (en) | Pharmaceutical capsules | |
HK89493A (en) | Pharmaceutical capsules containing ranitidine | |
EP0390930A4 (en) | Stable aqueous preparation of active vitamin d 3? | |
GB2215208B (en) | Transdermal administration of plant extracts | |
EP0285550A3 (en) | A percutaneous-administration-type pharmaceutical preparation of nitroglycerin | |
ZA897692B (en) | Triglycerides,composition comprising such triglycerides,and use of such composition | |
MY101916A (en) | Etoposide oral dosage form. | |
EP0194710A3 (en) | New derivative of fructose, its preparation and its uses | |
IL82726A (en) | Pharmaceutical compositions comprising anticonvulsively active 1-phenalkylimidazole-4-and/or-5-carboxamides and certain novel phenalkylimidazoles and their manufacture | |
ZA872676B (en) | Composition containing angiogenically active lipid containing molecules and a pharmaceutically acceptable carrier | |
IL85651A (en) | Preparation of optically active oxo-isoindolinyl derivatives,some such novel dextrorotary isomers and pharmaceutical compositions containing the novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998507590 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |